216 related articles for article (PubMed ID: 17389624)
1. Enoxaparin but not unfractionated heparin causes a dose-dependent increase in plasma TGF-beta 1 during haemodialysis: a cross-over study.
Naumnik B; Borawski J; Pawlak K; Mysliwiec M
Nephrol Dial Transplant; 2007 Jun; 22(6):1690-6. PubMed ID: 17389624
[TBL] [Abstract][Full Text] [Related]
2. Different effects of enoxaparin and unfractionated heparin on some thrombogenesis markers during hemodialysis: a cross-over study.
Naumnik B; Pawlak K; Myśliwiec M
Thromb Res; 2009 Feb; 123(4):631-6. PubMed ID: 18234290
[TBL] [Abstract][Full Text] [Related]
3. Different effect of unfractionated heparin and enoxaparin on circulating proangiogenic factors during hemodialysis: A cross-over study.
Naumnik B; Pawlak K; Myśliwiec M
Cytokine; 2007 Nov; 40(2):98-104. PubMed ID: 17920287
[TBL] [Abstract][Full Text] [Related]
4. Unfractionated heparin but not enoxaparin causes delayed plasma PAI-1 depletion in hemodialysis patients: a prospective study.
Naumnik B; Pawlak K; Mys'liwiec M
Clin Appl Thromb Hemost; 2009 Feb; 15(1):84-91. PubMed ID: 17895513
[TBL] [Abstract][Full Text] [Related]
5. Different effects of enoxaparin, nadroparin, and dalteparin on plasma TFPI during hemodialysis: a prospective crossover randomized study.
Naumnik B; Rydzewska-Rosołowska A; Myśliwiec M
Clin Appl Thromb Hemost; 2011 Oct; 17(5):480-6. PubMed ID: 20682597
[TBL] [Abstract][Full Text] [Related]
6. Over-dialysis plasma RANTES increase depends on heparin dose and cardiovascular disease status.
Naumnik B; Koc-Żórawska E; Myśliwiec M
Adv Med Sci; 2013; 58(2):311-9. PubMed ID: 23959669
[TBL] [Abstract][Full Text] [Related]
7. Attenuation of platelet reactivity by enoxaparin compared with unfractionated heparin in patients undergoing haemodialysis.
Aggarwal A; Whitaker DA; Rimmer JM; Solomon RJ; Gennari FJ; Sobel BE; Schneider DJ
Nephrol Dial Transplant; 2004 Jun; 19(6):1559-63. PubMed ID: 15034156
[TBL] [Abstract][Full Text] [Related]
8. High-dose tirofiban with enoxaparin and inflammatory markers in high-risk percutaneous intervention.
Walters DL; Ray MJ; Wood P; Perrin EJ; Bett JH; Aroney CN
Eur J Clin Invest; 2010 Feb; 40(2):139-47. PubMed ID: 20039931
[TBL] [Abstract][Full Text] [Related]
9. Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: a prospective study.
Naumnik B; Borawski J; Myśliwiec M
Nephrol Dial Transplant; 2003 Jul; 18(7):1376-82. PubMed ID: 12808176
[TBL] [Abstract][Full Text] [Related]
10. High plasma endostatin level unaffected by low-molecular weight heparin in hemodialysis patients--a preliminary report.
Rydzewska-Rosolowska A; Borawski J; Mysliwiec M
Adv Med Sci; 2009; 54(2):199-202. PubMed ID: 19758969
[TBL] [Abstract][Full Text] [Related]
11. Effects of unfractionated and low molecular weight heparins on plasma levels of hemostatic factors in patients with acute coronary syndromes.
Vila V; Martínez-Sales V; Réganon E; Peris E; Perez F; Ruano M; Aznar J
Haematologica; 2001 Jul; 86(7):729-34. PubMed ID: 11454528
[TBL] [Abstract][Full Text] [Related]
12. Elevated hepatocyte growth factor levels at the beginning of high-flux hemodialysis are due to heparin administration.
Christidou F; Bamichas G; Galaktidou G; Fragidis S; Gionanlis L; Frangia T; Bischiniotis T; Sombolos K
Ren Fail; 2008; 30(9):861-4. PubMed ID: 18925524
[TBL] [Abstract][Full Text] [Related]
13. HCV infection in haemodialysed patients: a role for serum IL-10 and TGF-beta1 in liver damage?
Burra P; Masier A; Morisco F; Di Leo V; Zorzi M; Senzolo M; Marchini F; Guido M; Canova D; Floreani A; Burroughs AK
Dig Liver Dis; 2008 Oct; 40(10):827-33. PubMed ID: 18372225
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post-certification study.
Klingel R; Schwarting A; Lotz J; Eckert M; Hohmann V; Hafner G
Kidney Blood Press Res; 2004; 27(4):211-7. PubMed ID: 15273423
[TBL] [Abstract][Full Text] [Related]
15. The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial.
White HD; Gallo R; Cohen M; Steg PG; Aylward PE; Bode C; Steinhubl S; Montalescot G
Am Heart J; 2009 Jan; 157(1):125-31. PubMed ID: 19081408
[TBL] [Abstract][Full Text] [Related]
16. Effect of unfractionated and low-molecular-weight heparin on OPG, sRANKL, and von Willebrand factor concentrations during hemodialysis.
Klejna K; Naumnik B; Koc-Żórawska E; Myśliwiec M
Clin Appl Thromb Hemost; 2014 May; 20(4):433-41. PubMed ID: 23104956
[TBL] [Abstract][Full Text] [Related]
17. Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACK-on to ENOXaparin (STACKENOX) study.
Drouet L; Bal dit Sollier C; Martin J
Am Heart J; 2009 Aug; 158(2):177-84. PubMed ID: 19619692
[TBL] [Abstract][Full Text] [Related]
18. Plateletpheresis does not cause long-standing platelet-derived growth factor release into the donor blood.
Zimmermann R; Loew D; Weisbach V; Strasser E; Ringwald J; Zingsem J; Eckstein R
Transfusion; 2005 Mar; 45(3):414-9. PubMed ID: 15752160
[TBL] [Abstract][Full Text] [Related]
19. Enoxaparin versus unfractioned heparin as anticoagulant for continuous venovenous hemodialysis: a randomized open-label trial.
Garcés EO; Victorino JA; Thomé FS; Röhsig LM; Dornelles E; Louzada M; Stifft J; de Holanda F; Veronese FV
Ren Fail; 2010 Jan; 32(3):320-7. PubMed ID: 20370447
[TBL] [Abstract][Full Text] [Related]
20. The AN69 ST haemodialysis membrane under conditions of two different extracorporeal circuit rinse protocols a comparison of thrombogenicity parameters.
Richtrova P; Opatrny K; Vit L; Sefrna F; Perlik R
Nephrol Dial Transplant; 2007 Oct; 22(10):2978-84. PubMed ID: 17597089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
